ONCAlert | Upfront Therapy for mRCC

Prostate Cancer VIEW MORE >>

Combining cabozantinib plus androgen-deprivation therapy as first-line therapy in patients with hormone-naïve metastatic prostate cancer yields promising clinical activity, according to the new single-arm phase II study, which was published in Clinical Cancer Research.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.